[go: up one dir, main page]

MX2017013879A - Composiciones que comprenden anakinra. - Google Patents

Composiciones que comprenden anakinra.

Info

Publication number
MX2017013879A
MX2017013879A MX2017013879A MX2017013879A MX2017013879A MX 2017013879 A MX2017013879 A MX 2017013879A MX 2017013879 A MX2017013879 A MX 2017013879A MX 2017013879 A MX2017013879 A MX 2017013879A MX 2017013879 A MX2017013879 A MX 2017013879A
Authority
MX
Mexico
Prior art keywords
compositions
anakinra
optionally
relates
present
Prior art date
Application number
MX2017013879A
Other languages
English (en)
Other versions
MX374705B (es
Inventor
Ebba Florin-Robertsson
Jonas Fransson
D Moore Barry
Original Assignee
Swedish Orphan Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab Publ filed Critical Swedish Orphan Biovitrum Ab Publ
Publication of MX2017013879A publication Critical patent/MX2017013879A/es
Publication of MX374705B publication Critical patent/MX374705B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden anakinra, regulador de pH, y opcionalmente al menos un osmolito y opcionalmente otros excipientes; además, la presente invención se refiere al uso de dichas composiciones para el tratamiento de, por ejemplo, trastornos oftálmicos.
MX2017013879A 2015-04-28 2016-04-27 Composiciones que comprenden anakinra. MX374705B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15165421 2015-04-28
PCT/EP2016/059398 WO2016174082A1 (en) 2015-04-28 2016-04-27 Compositions comprising anakinra

Publications (2)

Publication Number Publication Date
MX2017013879A true MX2017013879A (es) 2018-08-01
MX374705B MX374705B (es) 2025-03-06

Family

ID=53015628

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013879A MX374705B (es) 2015-04-28 2016-04-27 Composiciones que comprenden anakinra.

Country Status (15)

Country Link
US (1) US11324807B2 (es)
EP (1) EP3288536B1 (es)
JP (1) JP6769994B2 (es)
KR (1) KR102582560B1 (es)
CN (1) CN107645956B (es)
AU (1) AU2016256217B2 (es)
CA (1) CA2983783A1 (es)
DK (1) DK3288536T3 (es)
ES (1) ES2744605T3 (es)
IL (1) IL255275B (es)
MX (1) MX374705B (es)
RU (1) RU2728795C2 (es)
SG (1) SG11201708698XA (es)
WO (1) WO2016174082A1 (es)
ZA (1) ZA201707872B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020075918A (ja) * 2018-11-02 2020-05-21 千寿製薬株式会社 角膜上皮創傷治癒促進用の眼科用組成物
SG10201907137RA (en) * 2019-08-02 2021-03-30 Singapore Health Serv Pte Ltd Use of an osmolyte in manufacture of a medicament for treatment of ocular disorders
WO2022172284A1 (en) * 2021-02-11 2022-08-18 Gennova Biopharmaceuticals Ltd. Purification of a therapeutic protein
DE102021212692A1 (de) 2021-11-11 2023-05-11 Ursapharm Arzneimittel Gmbh Selbstemulgierende öl-in wasser-mikro- oder nanoemulsion so-wie emulgierende zusammensetzung

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6858409B1 (en) * 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
GEP20033082B (en) * 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
AU2005231822B2 (en) * 2004-04-02 2011-07-21 Swedish Orphan Biovitrum Ab (Publ) Methods of reducing aggregation of IL-1ra
MX2009006709A (es) * 2006-12-20 2009-07-02 Xoma Technology Ltd Tratamiento de enfermedades relacionadas con il-1beta.
WO2009025763A2 (en) * 2007-08-16 2009-02-26 Schepens Eye Research Institute Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
PT2222697E (pt) * 2007-11-01 2013-02-15 Perseid Therapeutics Llc Polipeptídeos imunossupressores e ácidos nucleicos
EP2219602A1 (en) * 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
ES2582928T3 (es) 2011-02-11 2016-09-16 Swedish Orphan Biovitrum Ab (Publ) Composiciones farmacéuticas exentas de citrato que comprenden anakinra
US20140314746A1 (en) 2013-03-13 2014-10-23 Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine Methods for treating or preventing fibrosis in subjects afflicted with scleroderma
KR102236926B1 (ko) * 2013-03-13 2021-04-06 세센 바이오, 아이엔씨. 안구 운반을 위한 키메릭 사이토카인 제제

Also Published As

Publication number Publication date
BR112017022942A2 (pt) 2018-07-17
ES2744605T3 (es) 2020-02-25
IL255275B (en) 2020-06-30
EP3288536B1 (en) 2019-06-26
RU2728795C2 (ru) 2020-07-31
DK3288536T3 (da) 2019-09-23
RU2017140495A3 (es) 2019-09-13
CN107645956A (zh) 2018-01-30
US20180110836A1 (en) 2018-04-26
KR20170142185A (ko) 2017-12-27
KR102582560B1 (ko) 2023-09-26
CA2983783A1 (en) 2016-11-03
IL255275A0 (en) 2017-12-31
AU2016256217B2 (en) 2020-04-16
ZA201707872B (en) 2020-01-29
WO2016174082A1 (en) 2016-11-03
AU2016256217A1 (en) 2017-12-07
SG11201708698XA (en) 2017-11-29
MX374705B (es) 2025-03-06
NZ737410A (en) 2024-05-31
US11324807B2 (en) 2022-05-10
JP6769994B2 (ja) 2020-10-14
JP2018514541A (ja) 2018-06-07
CN107645956B (zh) 2021-07-20
EP3288536A1 (en) 2018-03-07
RU2017140495A (ru) 2019-05-28

Similar Documents

Publication Publication Date Title
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
CU20160185A7 (es) Compuestos de heteroarilo para la inhibición de cinasa
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
BR112018004620A2 (pt) moduladores da expressão de kras
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
JOP20210050A1 (ar) معدلات تعبير pnpla3
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112017027721A2 (pt) formulação de alta concentração
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
BR112017011168A2 (pt) medicamentos para retardar a doença de parkinson
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112017014416A2 (pt) sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2017013879A (es) Composiciones que comprenden anakinra.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.

Legal Events

Date Code Title Description
FG Grant or registration